|OraSure Technologies, Inc.|
220 East First Street
United States - Map
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies. It also offers other diagnostic products, including immunoassays and other in vitro diagnostic tests that are used on other specimen types. The companys principal products comprise OraQuick ADVANCE HIV-1/2, OraQuick In-Home HIV Test, OraQuick HCV, OraSure QuickFlu rapid flu A&B test, OraSure, Oragene DX, Oragene DNA, Oragene DISCOVER, Oragene RNA, ORAcollect, OMNIgene DISCOVER, Performagene LIVESTOCK and Oragene ANIMAL, HEMAgen BUFFY COAT, PrepIT L2P, Intercept, MICRO-PLATE DOA Assays, Homogeneous DOA Assays, and professional and over-the-counter Cryosurgical Systems. In addition, it manufactures and sell oral fluid collection devices used to collect, stabilize, and store samples of genetic material for molecular testing in the clinical genetic testing, academic research, pharmacogenomics, personalized medicine, and animal genetics markets. Further, the company offers medical devices used for the removal of benign skin lesions by cryosurgery or freezing; certain immunoassay tests and reagents for insurance risk assessment, substance abuse testing, and forensic toxicology applications; an oral fluid Western blot HIV-1 confirmatory test for confirming positive HIV-1 test; and the FDA 510(k) cleared Q.E.D. rapid point-of-care saliva alcohol test. OraSure Technologies, Inc. sells its products to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians offices, and commercial and industrial entities in the United States and internationally. The company was founded in 1979 and is based in Bethlehem, Pennsylvania.
|OraSure Technologies, Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 9. The pillar scores are Audit: 1; Board: 6; Shareholder Rights: 8; Compensation: 9.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Douglas A. Michels ,
Chief Exec. Officer, Pres and Director
|Mr. Ronald H. Spair ,
Chief Financial Officer, Chief Operating Officer and Director
|Mr. Jack E. Jerrett ,
Sr. VP, Gen. Counsel and Sec.
|Mr. Anthony Zezzo II,
Exec. VP of Marketing and Sales
|Mr. Mark L. Kuna ,
Principal Accounting Officer, Sr. VP of Fin., Controller and Assistant Sec.
|Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|